Marcial: Avon’s Allure in Uncertain Times
The cosmetics giant’s products are recession-resistant, say Street pros, multiplied of whom rate the shares buy
Avon Products (AVP)—52-week stock price
By Gene Marcial
In good spells or bad, women slip on’t skip or skimp onward beauty products, whether they live in San Antonio, São Paolo, Moscow, or Beijing. That’s because most women consider cosmetics and special grace products as staples, or necessities in their quotidian lives, according to industry analysts. That suggests demand for such products is constant, inattentive of economic distress. The toiletries and cosmetics industry is at once "ranked to best a majority of industries under our review," wrote Kenneth Nugent, analyst at unconstrained research house Value Line (VALU), in a newly come note to clients.
That’s been a boon to Avon Products (AVP), the world’s largest direct seller of similar personal-care items. On Wall Street, Avon is among the companies analysts categorize as "defensive" plays that thrive even for the period of recessionary times. Of the 14 Street analysts who follow Avon, 10 recommend buying the stock and four reprimand it a hold.
Since late 2005, shares of Avon had been in an upward spiral, hitting a boastful of 45 on Aug. 5, 2008. But in October, the stock stumbled, to 23.94 on Oct. 24, from 41 on Oct. 1, when news leaked out that as June, Avon had started an internal inquiry into allegations that clear as day entertainment and other expenses may desire been "improperly incurred" in its operations in China. Avon voluntarily notified the Securities and Exchange Commission and the U.S. Justice Dept. with reference to the investigation, in the way that the Feds could determine whether the fellowship had violated the Foreign Corrupt Practices Act that bars U.S. companies from using bribery to acquire business overseas. Avon says the probe is still in its early staging.
another buying chance; fitBut Wall Street seems unperturbed. "When attempting to draw investment conclusions, we would start with materiality: China is 3% of sales and 0.5% of profits for Avon, to such a degree even a worst-case scenario [for the probe] would likely have no earnings implications," says Christopher Ferrara, an algebraist at Merrill Lynch (MER), who has retained his buy good opinion on Avon. "We speculate it’s in greater numbers likely that this investigation proves immaterial from an investing. prospect, even to the entire China operation, what one. itself is immaterial to Avon’s earnings (and to its multiple at current levels, in our view)," wrote Ferrara in a note to clients dated Oct. 21.
Ferrara points out that the price decline in the shares should be considered another opportunity to buy the fund. On Oct. 24, the stock had dropped to 24. His 12-month mark for the stock is 51, based forward his 2009 earnings estimate, excluding special charges, of $2.59 a share. (The stock is currently trading at 10 state of things the estimated 2009 earnings estimate, vs. a luxuriously of 35 in 2007.) The risks to his price target, Ferrara says, include a possible worsening slowdown in the U.S. profession and softer increase in the developing markets, especially in Brazil, which has accounted for a large dividend of Avon’s sales growth in recent years. (Merrill expects or intends to seek or receive compensation for investment banking services from Avon within the next three months.)
Indeed, most analysts have reduced their estimates on Avon’s sales and earnings inasmuch as of the global economic slowdown. Nonetheless, they remain upbeat about the stock.
"Even after slashing our earnings estimates, we still be attentive close to a 60% upside in Avon’s shares," says Nik Modi, analyst at investment tier UBS (UBS), who rates the stock a bribe with a 12-month price mark of 47, down from a former target of 52. The algebraist divide UBS’s 2008 earnings estimate on Avon to $2.11 a share from $2.25 and the 2009 estimate to $2.51 a share from $2.79. Avon earned $1.20 in 2007. (UBS owns Avon stock.)
"We are core prudent and cautious upon the body our revenue and earnings-per-share figures to reflect the current [macroeconomic] environment," says Modi. "But we believe that Avon is better positioned today to deal with these challenges."
5.4 million repsModi says investors are underestimating the countercyclical creator of Avon’s direct-selling business model and the cushion afforded by means of the company’s many cost-savings initiatives. Investors also underestimate, adds Modi, the "staplish" nature of beauty products in both the developed and developing countries. "Consumption in Avon’s lock opener markets is far from collapsing," says Modi, and "trends remain strong in Brazil, Russia, and China."
With Avon’s non-U.S. operations accounting roughly for 78% of sales and 80% of earnings, weak results in recent quarters in the U.S. (20% of sales) haven’t had a disastrous impact on the company’s growth. Some 5.4 million sales representatives emporium the company’s wares in 114 countries. Avon’session products include cosmetics, fragrance, and toiletries (70% of annual sales), jewelry, watches, apparel, and accessories (19%), and home products, gifts, and candles (11%).
Truly a global giant, Avon, what one. began operations in 1886, could well call for Keats’ immortal line, "a thing of beauty is a joy forever," as its inspiration. The beauty part, for the company and its investors: the millions of customers that use its products day in and day lacking. The joy: the prospect of solid, steady profits in dicey economic times.
Unless otherwise noted, not either the sources cited in Gene Marcial’s Stock Picks nor their firms hold positions in the stocks under discussion. Similarly, they own no investment banking or other monetary relationships with them.
View Slide Show
